This article is available to subscribers. Subscribe now. Already have an account? Sign in

PerspectiveFree Preview

Incentives for Drug Development — The Curious Case of Colchicine

List of authors.
  • Aaron S. Kesselheim, M.D., J.D.,
  • and Daniel H. Solomon, M.D., M.P.H.

In July 2009, the Food and Drug Administration (FDA) officially announced what physicians have long known — that the drug colchicine can effectively treat acute flares of gouty arthritis. The plant from which colchicine is derived was first used as a therapeutic agent for gout more than 3000 years ago in ancient Greece, and the tablet form has been widely available as a generic prescription drug in the United States since the 19th century. On the basis of evidence that had built up over the years, numerous consensus guidelines recommended colchicine as an effective second-line treatment for gout — for . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

This article (10.1056/NEJMp1003126) was published on April 14, 2010, and was updated on April 21, 2010, at NEJM.org.

Author Affiliations

From the Division of Pharmacoepidemiology and Pharmacoeconomics (A.S.K.) and the Division of Rheumatology (D.H.S.), Brigham and Women's Hospital, and Harvard Medical School — both in Boston.

Print Subscriber? Activate your online access.